Pure Bioscience, Inc 8-K, filed Feb 10, 2023
Pure Bioscience, Inc. (PURE)
About this 8-K
Pure Bioscience, Inc filed this 8-K on February 10, 2023, reporting on events of February 8, 2023.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
Pure Bioscience, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on February 08, 2023. Of the 111,356,485 shares of the Company’s common stock outstanding as of the record date, 65,965,992 shares, or 59.23%, were represented at the Annual Meeting either in person or by proxy.
A description of each matter voted upon at the Annual Meeting is described in detail in the Proxy Statement. The number of votes cast “For” and “Withheld” and “Against” and the number of “Abstentions” and “Broker Non-Votes” with respect to each matter voted upon are set forth below.
(1) Election of Directors. The Company’s stockholders elected each of Tom Y. Lee, CPA, Ivan Chen, Tom Myers, Kristin A. Taylor, David M. Rendall, Robert Bartlett, and Bernard Blotner with the approval of 96.67%, 99.19%, 98.33%, 96.60%, 97.38%, 97.35% and 97.34%, of the votes cast, respectively, to hold office until next year’s Annual Meeting of Stockholders and until their respective successors are elected and qualified. The following table shows the tabulation of the votes cast For and Withheld with respect to the election of each of the director nominees as well as the Broker Non-Votes submitted for each director nominee:
| Director | For | Withheld | Broker Non-Votes | |||||||||
| Tom Y. Lee, CPA | 52,417,512 | 1,805,553 | 11,742,927 | |||||||||
| Ivan Chen | 53,783,287 | 439,778 | 11,742,927 | |||||||||
| Tom Myers | 53,317,145 | 905,920 | 11,742,927 | |||||||||
| Kristin A. Taylor | 52,377,326 | 1,845,739 | 11,742,927 | |||||||||
| David M. Rendall | 52,804,580 | 1,418,485 | 11,742,927 | |||||||||
| Robert Bartlett | 52,786,761 | 1,436,304 | 11,742,927 | |||||||||
| Bernard Blotner | 52,782,415 | 1,440,650 | 11,742,927 | |||||||||
(2) Ratification of Auditors. The Company’s stockholders ratified the appointment of Weinberg & Company, P.A., with the approval of 99.87% of the votes cast, as the Company’s independent registered public accounting firm for the fiscal year ending July 31, 2023. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions submitted on this proposal:
| For | Against | Abstentions | ||||||||
| 65,354,828 | 78,962 | 532,202 | ||||||||
(3) Executive Compensation. The Company’s stockholders, on a non-binding, advisory basis, approved the compensation of the Company’s named executive officers, with the approval of 96.84% of the votes cast, as disclosed in the Proxy Statement. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions and Broker Non-Votes submitted on this proposal:
| For | Against | Abstentions | Broker Non-Votes | |||||||||||
| 49,699,924 | 1,617,819 | 2,905,322 | 11,742,927 | |||||||||||
No other items were presented for stockholder approval at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PURE BIOSCIENCE, INC. | ||
| Dated: February 10, 2023 | By: | /s/ Tom Y. Lee |
| Tom Y. Lee | ||
| Chief Executive Officer | ||